Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43DC.A.TO 0.3NESN-SIX 0MCK 31.3
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
SELL

Pfizer Inc(PFE)

Aug 09, 2006
Big issue is 20% of revenue and a larger % of profits comes from one drug, Lipitor, which will get generic competition. Sold their consumer business and have other products in the pipeline and they are buying back mountains of its own stock. Dividend share is significant.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$26.15

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 03, 2006
A defensive position. Very cheap. Lots of value and seems to have momentum.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$25.51

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 02, 2006
(A Top Pick May 10/06. No change.) A large cap stock that is going into transition. Sold their consumer products area. Wants to see how this affects the balance sheet. 4% dividend. Still likes.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.61

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 25, 2006
All the major drug stocks are starting to act better. In the state of market, money moves from risky stocks to defensive stocks. Has a great yield. A good place to be.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.96

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 24, 2006
Under performed Merck (MRK-N) quite dramatically. Between these two would prefer to own Merck. Making a bit of a bottoming pattern which is constructive. Needs to take out some resistance and if they can break through the $26 level there could be some good upside.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$24.79

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 21, 2006
It has a model price of $33.93 which is a 42% positive differential. Have now sold their consumer division and their balance sheet is going to be a lot smaller. You get the same earnings, but with a smaller balance sheet, which creates, value.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.83

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 12, 2006
The drug sector continues to be weak in general and is a group that has under performed during the last 2/3 years. This one has even under performed the group.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$23.18

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 11, 2006
Have cleared their problems with Cellebrex. Selling their consumers product division for $16 billion cash. This will probably go to share repurchase, increased dividends and acquisition of promising drugs from small companies. Cheap.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.49

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
BUY

Pfizer Inc(PFE)

Jun 14, 2006
Great dividend yield. Probably one of the worst performing sectors in the S&P. Lots of cost cutting opportunities. A number of drugs along the pipeline. Trading at around 8/9 X earnings. Pristine balance sheet.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$23.11

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 14, 2006
A real defensive story. Have tremendous internal cash flow. Have a sound dividend and they buy back stocks. A real value play. New drugs coming out are really solid.
Photo of Paul Gardner, CFAPaul Gardner, CFA
Owned
Unlock Rating
$23.11

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 30, 2006
Got rid of a lot of their past problems. The whole drug sector has been a difficult place to be because of pricing pressures, lawsuits, etc. The worst is now over. Large pharmaceuticals are international, so as the US$ drops, their foreign assets increase.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.58

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 26, 2006
A cheap company. The sector is cheap. Really great yield. Expects they will be getting rid of their consumer products division this year, which will give the stock a boost.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$23.58

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 17, 2006
Near 4% yield which is very attractive. Good level to buy. Trading at about 12 X earnings. Gives about 35% return on equity. No debt.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$24.27

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 10, 2006
His model price is $38, a 49% positive differential. Pays a nice fat dividend.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.04

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 09, 2006
Has an ace dividend yield of about 3%. Turning things around. Have a good pipeline. Has there consumer products operation up for sale but thinks they will spin it out to the shareholders. Very little downside risk.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$25.51

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 616 to 630 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

IESC -10.86$313.26
NTR.TO -2.19$100.68
TFPM 0$
OGC.TO 0.08$43.3
SLB -0.71$53.29

Today's Top Picks

MNT.TO 0.69$69.95
COPX 1.79$96.32
U.U.TO 0.5$20.92
SII.TO 2.94$190.13
IPCO.TO -0.43$34.79

Popular Articles

Latest Sell Signals

RKLB -1.37$66.91
INTC 0.22$87.48
MSFT 4.4$491.71
WSP.TO -2.98$189.3
CLS.TO 16.21$423.57

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like